/
Oncology
Gastric Cancer
210
Pipeline Programs↗
329
Active Trials↗
117
Companies Involved↗
Gastric Cancer is a highly competitive landscape with 210 programs across 117 companies. The most active players are AstraZeneca, Ono Pharmaceutical Co. Ltd, Suzhou Suncadia Biopharmaceuticals Co., Ltd.. 62 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical29
Phase 112
Phase 2107
Phase 362
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
146 of 194 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 194 classified programs, each share of the total. Modality classified for 98% of 210 pipeline programs.
Analysis
Trial Status
1,087
clinical trials
Completed350 · 32%
Unknown status325 · 30%
Recruiting162 · 15%
Not yet recruiting97 · 9%
Active, not recruiting66 · 6%
Terminated60 · 6%
Other27 · 2%
Clinical Trials
Trial Activity
1087 trials
Page 1 of 73
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)